top of page

Zevra Therapeutics Media Release | January 8, 2024

Zevra Therapeutics Receives FDA Acceptance Of Resubmission Of NDA For Arimoclomol As A Treatment For Niemann-Pick Disease Type C


Read the full statement from Zevra Therapeutics here:



Here is a summary of the article:

  • Zevra Therapeutics Resubmits NDA for Arimoclomol: The company announced that the FDA has accepted the resubmission of the NDA for arimoclomol, a potential treatment for Niemann-Pick disease type C.

  • PDUFA Action Date and Advisory Committee: The FDA has assigned a PDUFA action date of June 21, 2024, and intends to present the resubmission for discussion in an advisory committee.

 

To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."


Ways to support NP-C in Australia:

10 views0 comments
bottom of page